Lipigon: Safety Demonstrated in the SAD Part with Lipisense - Redeye
Redeye comments on Lipigon's third quarter report, in particular on the SAD and recently initiated MAD part of the phase I trial with Lipisense and on the financial situation.
ANNONS
Redeye comments on Lipigon's third quarter report, in particular on the SAD and recently initiated MAD part of the phase I trial with Lipisense and on the financial situation.